ATE454138T1 - Tablette mit modifizierter freisetzung von bupropion hydrochlorid - Google Patents

Tablette mit modifizierter freisetzung von bupropion hydrochlorid

Info

Publication number
ATE454138T1
ATE454138T1 AT03818223T AT03818223T ATE454138T1 AT E454138 T1 ATE454138 T1 AT E454138T1 AT 03818223 T AT03818223 T AT 03818223T AT 03818223 T AT03818223 T AT 03818223T AT E454138 T1 ATE454138 T1 AT E454138T1
Authority
AT
Austria
Prior art keywords
modified release
release tablet
bupropion hydrochloride
bupropion
hydrochloride
Prior art date
Application number
AT03818223T
Other languages
English (en)
Inventor
Werner Oberegger
Okpo Eradiri
Fang Zhou
Paul Maes
Original Assignee
Biovail Lab Int Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34192557&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE454138(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biovail Lab Int Srl filed Critical Biovail Lab Int Srl
Application granted granted Critical
Publication of ATE454138T1 publication Critical patent/ATE454138T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03818223T 2003-08-08 2003-08-08 Tablette mit modifizierter freisetzung von bupropion hydrochlorid ATE454138T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2003/024700 WO2005016318A1 (en) 2003-08-08 2003-08-08 Modified-release tablet of bupropion hydrochloride

Publications (1)

Publication Number Publication Date
ATE454138T1 true ATE454138T1 (de) 2010-01-15

Family

ID=34192557

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03818223T ATE454138T1 (de) 2003-08-08 2003-08-08 Tablette mit modifizierter freisetzung von bupropion hydrochlorid

Country Status (29)

Country Link
US (2) US20050238718A1 (de)
EP (1) EP1575565B1 (de)
JP (1) JP2007521231A (de)
KR (1) KR101087464B1 (de)
CN (1) CN1819821B (de)
AP (1) AP1899A (de)
AT (1) ATE454138T1 (de)
AU (1) AU2003264002B2 (de)
BR (1) BRPI0318456B8 (de)
CA (1) CA2524300C (de)
CR (1) CR8056A (de)
CY (1) CY1109955T1 (de)
DE (1) DE60330909D1 (de)
DK (1) DK1575565T3 (de)
EA (1) EA013737B1 (de)
ES (1) ES2336913T3 (de)
HR (1) HRP20050625B1 (de)
IL (1) IL171870A (de)
IS (1) IS2779B (de)
ME (2) ME00391B (de)
MX (1) MXPA05012637A (de)
NO (2) NO335271B1 (de)
NZ (1) NZ544281A (de)
PL (1) PL196544B1 (de)
PT (1) PT1575565E (de)
RS (2) RS51934B (de)
SI (1) SI1575565T1 (de)
TN (1) TNSN06016A1 (de)
WO (1) WO2005016318A1 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101167579B1 (ko) 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물
DK1663197T3 (da) 2003-09-09 2008-01-07 Fumapharm Ag Anvendelse af fumarsyrederivater til behandling af hjerteinsuffiens og astma
SI1799196T1 (sl) 2004-10-08 2016-10-28 Forward Pharma A/S Farmacevtski sestavki z nadzorovanim sproščanjem, obsegajoči ester fumarne kisline
US7241805B2 (en) 2005-06-27 2007-07-10 Biovail Laboratories, Inc. Modified release formulations of a bupropion salt
US7645802B2 (en) * 2005-06-27 2010-01-12 Biovail Laboratories International Srl. Bupropion hydrobromide and therapeutic applications
US7671094B2 (en) * 2005-06-27 2010-03-02 Biovail Laboratories International S.R.L. Bupropion hydrobromide and therapeutic applications
WO2007011708A2 (en) 2005-07-15 2007-01-25 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
ES2691646T3 (es) 2005-07-15 2018-11-28 Micell Technologies, Inc. Revestimientos poliméricos que contienen polvo de fármaco de morfología controlada
PT2135603E (pt) 2005-11-22 2013-04-03 Orexigen Therapeutics Inc Composições e métodos para aumentar a sensibilidade à insulina
PL1954241T3 (pl) * 2005-11-28 2013-03-29 Orexigen Therapeutics Inc Formulacja zonisamidu o przedłużonym uwalnianiu
CA2996768C (en) 2006-04-26 2020-12-08 Micell Technologies, Inc. Coatings containing multiple drugs
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
BRPI0715959A2 (pt) * 2006-08-21 2013-07-30 Jubilant Organosys Ltd composiÇço farmacÊutica de liberaÇço modificada de cloridrato de bupropion
JP5336382B2 (ja) 2006-10-23 2013-11-06 ミセル テクノロジーズ、インコーポレイテッド コーティングの間に基板を荷電するためのホルダー
DE602007005402D1 (de) 2006-11-09 2010-04-29 Orexigen Therapeutics Inc Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
CN101711137B (zh) 2007-01-08 2014-10-22 米歇尔技术公司 具有可生物降解层的支架
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
CN101815540B (zh) * 2007-05-25 2015-08-19 米歇尔技术公司 用于医疗器材涂层的聚合物膜
US20100203128A1 (en) * 2007-08-07 2010-08-12 Biovail Laboratories International Srl Bupropion hydrobromide and therapeutic applications
US20100291225A1 (en) * 2008-01-14 2010-11-18 Jubilant Organosys Ltd. Stabilized Sustained Release Composition of Bupropion Hydrochloride and Process For Preparing the Same
CA2721832C (en) 2008-04-17 2018-08-07 Micell Technologies, Inc. Stents having bioabsorbable layers
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
WO2010009335A1 (en) 2008-07-17 2010-01-21 Micell Technologies, Inc. Drug delivery medical device
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US8834913B2 (en) 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
EP2564839B1 (de) 2009-01-09 2016-05-11 Forward Pharma A/S Pharmazeutische Formulierung mit einem oder mehreren Fumarsäureestern in einer Erosionsmatrix
CN102481195B (zh) 2009-04-01 2015-03-25 米歇尔技术公司 涂覆支架
EP3366326A1 (de) 2009-04-17 2018-08-29 Micell Technologies, Inc. Stents mit gesteuerter elution
EP2453834A4 (de) 2009-07-16 2014-04-16 Micell Technologies Inc Medizinische wirkstofffreisetzungsvorrichtung
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
EP2531140B1 (de) 2010-02-02 2017-11-01 Micell Technologies, Inc. Stent und stenteinsatzsystem mit verbesserter einsetzbarkeit
MX391660B (es) 2010-03-24 2025-03-21 Jazz Pharmaceuticals Inc Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
WO2011133655A1 (en) 2010-04-22 2011-10-27 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
WO2012009684A2 (en) 2010-07-16 2012-01-19 Micell Technologies, Inc. Drug delivery medical device
WO2012166819A1 (en) 2011-05-31 2012-12-06 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
US8808734B2 (en) * 2011-07-11 2014-08-19 Full Spectrum Laboratories Limited Cannabinoid formulations
US10117972B2 (en) 2011-07-15 2018-11-06 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
PL4104824T3 (pl) 2012-06-06 2025-11-12 Nalpropion Pharmaceuticals Llc Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym
CN110269959A (zh) 2013-03-12 2019-09-24 脉胜医疗技术公司 可生物吸收的生物医学植入物
WO2014186532A1 (en) 2013-05-15 2014-11-20 Micell Technologies, Inc. Bioabsorbable biomedical implants
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
GB2561333B (en) 2017-02-17 2020-06-03 Bo Soederpalm Treatment of alcohol use disorder
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
CA3092076A1 (en) * 2018-02-23 2019-08-29 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
BR112021006027A2 (pt) 2018-11-19 2021-06-29 Jazz Pharmaceuticals Ireland Limited formulações de fármaco resistente a álcool
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
CN110200947A (zh) * 2019-06-27 2019-09-06 深圳市泛谷药业股份有限公司 一种安非他酮肠溶缓释微丸胶囊及其制备方法
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
US12582622B2 (en) 2020-10-08 2026-03-24 Jazz Pharmaceuticals Ireland Limited Sodium oxybate to treat idiopathic hypersomnia
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN121038779A (zh) 2023-02-03 2025-11-28 特瑞斯制药公司 每晚一次的低钠羟丁酸盐组合物
US12083080B2 (en) 2023-12-04 2024-09-10 Richard Louis Price Therapeutic methods using bupropion hydrobromide
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3885046A (en) * 1969-12-04 1975-05-20 Burroughs Wellcome Co Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression
US3885048A (en) * 1971-02-08 1975-05-20 James J Liggett Method for preparing simulated meat, fish and dairy products
US4361545A (en) 1979-05-21 1982-11-30 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion
US4882167A (en) 1983-05-31 1989-11-21 Jang Choong Gook Dry direct compression compositions for controlled release dosage forms
USRE33994E (en) * 1983-08-16 1992-07-14 Burroughs Wellcome Co. Pharmaceutical delivery system
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4851229A (en) * 1983-12-01 1989-07-25 Alza Corporation Composition comprising a therapeutic agent and a modulating agent
DK62184D0 (da) 1984-02-10 1984-02-10 Benzon As Alfred Diffusionsovertrukket polydepotpraeparat
US5082655A (en) * 1984-07-23 1992-01-21 Zetachron, Inc. Pharmaceutical composition for drugs subject to supercooling
US4629621A (en) * 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US4769027A (en) * 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
DE3485618D1 (de) 1984-08-17 1992-04-30 Wellcome Found Zusammensetzung zur kontrollierten abgabe eines wirkstoffes und ihre herstellung.
EP0197751B1 (de) * 1985-03-29 1990-07-18 Shinko Electric Co. Ltd. Eisenbahnfahrzeug mit Linearmotor
US4797286A (en) * 1985-11-12 1989-01-10 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
US4847092A (en) * 1985-11-12 1989-07-11 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
IT1191674B (it) 1986-03-07 1988-03-23 Eurand Spa Formulazioni per la preparazione di farmaci a rilascio prolungato adatte alla somministrazione per via orale
US4880622A (en) 1986-05-20 1989-11-14 Research Corporation Technologies, Inc. Water-soluble phosphazene polymers having pharmacological applications
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
CH668553A5 (de) * 1987-02-02 1989-01-13 Mepha Ag Arzneimittel mit verzoegerter wirkstofffreisetzung.
US5200193A (en) 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
US4837980A (en) * 1987-07-01 1989-06-13 The Uniroyal Goodrich Tire Company Method and apparatus for tire uniformity correction
US4792452A (en) 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
US4795641A (en) * 1987-08-20 1989-01-03 Eastman Kodak Company Polymer blends having reverse phase morphology for controlled delivery of bioactive agents
US5187150A (en) * 1987-10-14 1993-02-16 Debiopharm S.A. Polyester-based composition for the controlled release of polypeptide medicinal substances
JPH02257309A (ja) * 1989-03-30 1990-10-18 Fanuc Ltd Ｎｃプログラムの描画方法
US5030457A (en) * 1989-08-28 1991-07-09 Pharmaceutical Delivery Systems, Inc. Bioerodible polymers useful for the controlled release of therapeutic agents
EP0418596A3 (en) * 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
GB2245559A (en) * 1990-06-25 1992-01-08 Farmos Oy Bioceramic system for delivery of a bioactive compound.
DE9190107U1 (de) * 1990-08-07 1993-12-16 Pfizer Inc., New York, N.Y. Abgabe-Vorrichtung mit durch Grenzflächen-Polymerisation erhaltenen Membranen
US5431922A (en) * 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
US5169638A (en) 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
ES2140458T3 (es) * 1992-04-15 2000-03-01 Stanford Res Inst Int Aislamiento de esteroides que contienen una funcionalidad 5,7-dieno de una mezcla de esteroles.
GB9217295D0 (en) * 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
ES2127835T3 (es) * 1992-10-26 1999-05-01 Sanol Arznei Schwarz Gmbh Procedimiento para la preparacion de microcapsulas.
CA2150019C (en) * 1992-11-30 1999-01-05 Scott M. Herbig Supported liquid membrane delivery devices
US5656291A (en) * 1994-03-16 1997-08-12 Pharmacia & Upjohn Aktiebolag Controlled release preparation
SE9301057L (sv) * 1993-03-30 1994-10-01 Pharmacia Ab Beredning med kontrollerad frisättning
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US5541231A (en) * 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5523095A (en) * 1993-12-15 1996-06-04 Eastman Chemical Company Controlled release matrix system using cellulose acetate/polyvinylpyrrolidone blends
US5535556A (en) * 1994-04-18 1996-07-16 Hughes, Jr.; John P. Basement wall construction
US6020002A (en) * 1994-06-14 2000-02-01 Fuisz Technologies Ltd. Delivery of controlled-release system(s)
US5567439A (en) * 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
US5958458A (en) 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
US5478572A (en) 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
FR2725623A1 (fr) * 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
US5558879A (en) 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
US6558708B1 (en) * 1995-05-17 2003-05-06 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
US5654005A (en) * 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
CA2192782C (en) * 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
US5762961A (en) * 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
AU2021997A (en) 1996-03-08 1997-09-22 Nycomed Danmark A/S Modified release multiple-units dosage composition
US6274171B1 (en) * 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
US6096339A (en) * 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
FR2747921B1 (fr) * 1996-04-24 1998-10-30 Adir Comprime matriciel permettant la liberation prolongee du sel de sodium de tianeptine apres administration par voie orale
HRP970493A2 (en) * 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
SI9600330A (sl) * 1996-11-11 1998-06-30 KEKO VARICON d.o.o. Zaščitna komponenta z več funkcijami
WO1998030208A1 (en) * 1997-01-10 1998-07-16 Abbott Laboratories Tablet for the controlled release of active agents
CA2216215A1 (en) 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
US6641614B1 (en) 1997-05-01 2003-11-04 Spinal Concepts, Inc. Multi-variable-height fusion device
US6168873B1 (en) 1997-05-29 2001-01-02 Canon Kabushiki Kaisha Electrode substrate and recording medium
US6004582A (en) 1997-05-30 1999-12-21 Laboratorios Phoenix U.S.A, Inc. Multi-layered osmotic device
ATE302597T1 (de) * 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
IL133080A0 (en) * 1997-07-01 2001-03-19 Pfizer Sertraline salts and sustained-release dosage forms of sertraline
US6287587B2 (en) 1997-07-15 2001-09-11 Takeda Chemical Industries, Ltd. Process for producing sustained-release preparation by in-water drying
ES2234139T3 (es) 1997-08-11 2005-06-16 Alza Corporation Forma de dosificacion de un agente activo de liberacion prolongada adaptada para la retencion gastrica.
US5840334A (en) 1997-08-20 1998-11-24 Fuisz Technologies Ltd. Self-binding shearform compositions
AU9062998A (en) * 1997-09-11 1999-03-29 Nycomed Danmark A/S Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (nsaids)
US6391336B1 (en) * 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
US6342250B1 (en) * 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
AU750808B2 (en) * 1997-10-03 2002-07-25 Cary Medical Corporation Compositon for the treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant or anti-anxiety drug
IT1297461B1 (it) * 1997-10-29 1999-12-17 Ciocca Maurizio Preparazione di compresse a rilascio controllato a base di complessi tra carragenano e farmaci basici solubili
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US6221917B1 (en) 1997-12-30 2001-04-24 American Home Products Corporation Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5968553A (en) 1997-12-30 1999-10-19 American Home Products Corporation Pharmaceutical composition containing bupropion hydrochloride and an inorganic acid stabilizer
US5919484A (en) * 1998-01-15 1999-07-06 Isp Investments Inc. Controlled release, drug-delivery tableted composition including a polymer of a vinyl amide, (meth)acrylic acid, a long chain alkyl (meth)acrylate and a lower alkyl (meth)acrylate
WO1999038499A2 (en) 1998-01-29 1999-08-05 Sepracor Inc. Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (-)-bupropion
WO1999038503A1 (en) 1998-01-29 1999-08-05 Sepracor Inc. Pharmacological uses of optically pure (+)-bupropion
WO1999038502A1 (en) 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (+)-bupropion
WO1999047128A1 (en) 1998-03-19 1999-09-23 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
US6372254B1 (en) * 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
US6143325A (en) 1998-06-05 2000-11-07 Bristol-Myers Squibb Company Nefazodone dosage form
US6153223A (en) * 1998-06-05 2000-11-28 Watson Pharmaceuticals, Inc. Stabilized pharmaceutical compositions
US6117452A (en) 1998-08-12 2000-09-12 Fuisz Technologies Ltd. Fatty ester combinations
US6129931A (en) 1998-09-03 2000-10-10 Isp Investments Inc. Controlled-release, drug-delivery tableted composition including a complex between poly(maleic diacid-alkyl vinyl ether) and polyvinylpyrrolidone
IL141762A0 (en) * 1998-10-01 2002-03-10 Novartis Ag New oral formulations
US6096341A (en) * 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride
US6033686A (en) * 1998-10-30 2000-03-07 Pharma Pass Llc Controlled release tablet of bupropion hydrochloride
US6270805B1 (en) * 1998-11-06 2001-08-07 Andrx Pharmaceuticals, Inc. Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
DE69915346T2 (de) * 1998-12-17 2004-07-22 Alza Corp., Mountain View Umwandlung von flüssigkeitsgefüllten gelatinkapseln in systeme mit gesteuerter wirkstoffabgabe durch mehrfache beschichtungen
US6238697B1 (en) * 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
US6635281B2 (en) 1998-12-23 2003-10-21 Alza Corporation Gastric retaining oral liquid dosage form
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
US6342249B1 (en) * 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
CA2259730A1 (en) 1999-01-18 2000-07-18 Bernard Charles Sherman Sustained release tablets containing bupropion hydrochloride
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US6589553B2 (en) * 2001-02-08 2003-07-08 Andrx Pharmaceuticals, Inc. Controlled release oral dosage form
US6210716B1 (en) * 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation
US6441046B1 (en) * 1999-03-19 2002-08-27 Abbott Gmbh & Co. Kg Control of metabolism
FR2791809B1 (fr) * 1999-04-01 2001-06-15 Air Liquide Procede et dispositif de traitement d'articles stockes dans des conteneurs et appareil de stockage dote d'un tel dispositif
WO2000059481A1 (en) * 1999-04-06 2000-10-12 Pharmaquest Ltd. PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT
US6116501A (en) 1999-04-22 2000-09-12 The Procter & Gamble Company Stackable, self-supporting container with lid-alignment feature
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
FR2795326B1 (fr) 1999-06-28 2001-08-31 Adir Composition pharmaceutique solide thermoformable a liberation controlee
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6387403B1 (en) * 1999-09-15 2002-05-14 Alza Corporation Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing
CA2324813A1 (en) 1999-11-10 2001-05-10 Susan Beth Sobolov-Jaynes Combination treatment for depression and anxiety
US6352721B1 (en) * 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
US7115297B2 (en) * 2000-02-22 2006-10-03 Suzanne Jaffe Stillman Nutritionally fortified liquid composition with added value delivery systems/elements/additives
US6372252B1 (en) * 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US6306436B1 (en) * 2000-04-28 2001-10-23 Teva Pharmaceuticals Usa, Inc. Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
US20040156872A1 (en) 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
US6541532B1 (en) * 2000-06-02 2003-04-01 Milliken & Company Scorch inhibiting compositions for polyurethane foams
US7678387B2 (en) * 2000-06-06 2010-03-16 Capricorn Pharma, Inc. Drug delivery systems
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
CA2420597C (en) * 2000-08-31 2011-05-17 Rtp Pharma Inc. Milled particles
US6540990B2 (en) 2000-09-22 2003-04-01 Gerard M. Nolan Physiological method of improving vision
US6491947B2 (en) 2000-11-03 2002-12-10 Chemlink Laboratories, Llc Expanded perborate salt, use, and method of production
CN1352938A (zh) * 2000-11-14 2002-06-12 北京万全阳光医药科技有限公司 盐酸安非他酮缓释片
EP1357898A4 (de) 2001-02-08 2005-07-13 Andrx Pharmaceuticals Inc Verbesserte orale arzneiform mit protrahierter wirkstoffreigabe
WO2002094323A1 (en) 2001-05-22 2002-11-28 Glaxo Group Limited Weight reduction or weight controlling composition
US6960357B2 (en) * 2001-05-25 2005-11-01 Mistral Pharma Inc. Chemical delivery device
DE10126163A1 (de) 2001-05-30 2002-12-05 Degussa Pharmazeutische Zubereitungen
ITMI20011457A1 (it) * 2001-07-09 2003-01-09 Valpharma Sa Composizione farmaceutica a rilascio modificato contenente bupropionehc1 come sostanza attiva
US20030068356A1 (en) 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
US20030044462A1 (en) * 2001-08-20 2003-03-06 Kali Laboratories, Inc. Sustained release tablets containing bupropion hydrochloride
US20030072802A1 (en) * 2001-10-11 2003-04-17 R.T. Alamo Ventures, Inc. Sustained release topiramate
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6723340B2 (en) * 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US7815936B2 (en) * 2001-10-30 2010-10-19 Evonik Degussa Gmbh Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
US20040037879A1 (en) * 2001-11-02 2004-02-26 Adusumilli Prasad S. Oral controlled release forms useful for reducing or preventing nicotine cravings
MXPA04006163A (es) * 2001-12-20 2004-11-01 Pharmacia Corp Formas de dosis de liberacion sostenida del orden-cero y metodo de fabricacion de las mismas.
DE60312642T2 (de) * 2002-01-09 2007-11-29 Ucb Farchim S.A. Pharmazeutische zusammensetzung mit modifizierter freisetzung
DE10200813A1 (de) 2002-01-11 2003-09-18 Krauss Maffei Kunststofftech Spritzgießmaschine mit zumindest einer Säule
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
AU2003211146B2 (en) * 2002-02-21 2007-07-19 Valeant International (Barbados) Srl Controlled release dosage forms
IN192747B (de) 2002-04-15 2004-05-15 Ranbaxy Lab Ltd
KR100483588B1 (ko) * 2002-07-11 2005-04-18 주식회사 하이닉스반도체 난드형 플래시 메모리 소자의 셀렉트 라인 형성 방법
US20040115263A1 (en) * 2002-08-26 2004-06-17 Robertson David W. Use of bupropion for treating restless legs syndrome
US6913768B2 (en) * 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
US20040132826A1 (en) 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
WO2004087175A1 (en) * 2003-04-04 2004-10-14 Pharmacia Corporation Oral extended release compressed tablets of multiparticulates
AR045423A1 (es) 2003-05-13 2005-10-26 Cephalon Inc Combinaciones de analiticos y antidepresivos

Also Published As

Publication number Publication date
AP2005003463A0 (en) 2005-12-31
EP1575565A4 (de) 2007-05-02
DK1575565T3 (da) 2010-04-12
IL171870A (en) 2011-08-31
PL196544B1 (pl) 2008-01-31
BRPI0318456B8 (pt) 2021-05-25
CA2524300A1 (en) 2005-02-24
KR20060071392A (ko) 2006-06-26
NO20053245D0 (no) 2005-07-01
WO2005016318A1 (en) 2005-02-24
US20050238718A1 (en) 2005-10-27
HRP20050625B1 (hr) 2015-08-28
BRPI0318456B1 (pt) 2021-01-05
PL378539A1 (pl) 2006-02-06
RS20060132A (sr) 2008-06-05
NZ544281A (en) 2008-07-31
IS2779B (is) 2012-05-15
KR101087464B1 (ko) 2011-11-25
EP1575565A1 (de) 2005-09-21
JP2007521231A (ja) 2007-08-02
CN1819821A (zh) 2006-08-16
EA013737B1 (ru) 2010-06-30
RS51934B (sr) 2012-02-29
CY1109955T1 (el) 2014-09-10
DE60330909D1 (de) 2010-02-25
CN1819821B (zh) 2010-10-13
NO20053245L (no) 2005-10-04
CR8056A (es) 2008-07-29
EP1575565B1 (de) 2010-01-06
HRP20050625A2 (hr) 2008-07-31
EA200600206A1 (ru) 2006-06-30
MXPA05012637A (es) 2006-02-24
HK1083193A1 (en) 2006-06-30
MEP3608A (en) 2011-05-10
SI1575565T1 (sl) 2010-04-30
US7537784B2 (en) 2009-05-26
ES2336913T3 (es) 2010-04-19
AU2003264002B2 (en) 2010-09-02
TNSN06016A1 (en) 2007-10-03
ME00391B (me) 2011-10-10
CA2524300C (en) 2008-10-28
AP1899A (en) 2008-10-10
NO2015003I1 (no) 2015-02-16
IS7930A (is) 2005-07-01
NO335271B1 (no) 2014-10-27
PT1575565E (pt) 2010-03-03
BR0318456A (pt) 2006-09-12
US20060228415A1 (en) 2006-10-12
AU2003264002A1 (en) 2005-03-07

Similar Documents

Publication Publication Date Title
DE60330909D1 (de) Tablette mit modifizierter freisetzung von bupropion hydrochlorid
DE602004026719D1 (de) Ür tablette
ATE456368T1 (de) Reboxetin enthaltende tablette mit verzögerter wirkstoffabgabe
SK4326U (sk) Farmaceutická kompozícia s predĺženým uvoľňovaním
HRP20130114T1 (xx) Farmaceutski oblik s brzim oslobađanjem sinakalcet hci
NO20052914D0 (no) Terapeutiske forbindelser
DE602004017700D1 (de) Transmukosen verabreichung
IS8320A (is) N-staðgengnir pýrasólýl-amidýl-bensimidasólýl
PL360967A1 (en) Pharmaceutical compound containing donepezyl hydrochloride
DK1658263T3 (da) Aminobenzophenonforbindelser
AU2003216620A8 (en) Method of stabilizing bupropion hydrochloride tablets
DK1587478T3 (da) Farmaceutisk sammensætning
SK4325U (sk) Farmaceutická kompozícia s postupným uvoľňovaním
ATE546141T1 (de) Pharmazeutisches injektionspräparat
ATE389392T1 (de) Paracetamol enthaltende tablette
NO20044188L (no) Kontrollerte frigjoringsdoseformer
DE602004014804D1 (de) Haltenden tabletten
DE50304722D1 (de) Fungizide Wirkstoffkombinationen
ATE514681T1 (de) N-substituierte pyrazolylcarboxanilide
NO20034952D0 (no) Farmasöytiske forbindelser
DE602004002473D1 (de) Herstellung von quinapril hydrochlorid
FR2877288B1 (fr) Tablette escamotable
AU2003238590A1 (en) Tablets comprising ciprofloxacin hydrochloride
ATA16852004A (de) Tablette
DE112004001429D2 (de) Pharmazeutischer Wirkstoff

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1575565

Country of ref document: EP